Rodman & Renshaw Reiterates Geron Market Outperform, $9 PT - iPath Series B Carbon Exchange-Traded Notes (ARCA:GRN)

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.

Rodman & Renshaw reiterated its Geron (NASDAQ: GRN) Market Outperform / Speculative Risk rating and $9 price target in a research report published today.In the report, Rodman & Renshaw states, "With the spinal cord injury trial enrolling, a broad Phase 2 program for Imetelstat underway, and partnerships with GE Healthcare and AngioChem, we believe Geron represents an attractive opportunity for the risk-oriented, long-term investor."Shares of Geron were trading at $3.60 at the time of posting, down 3.61% from Monday's market close.

27% profits every 20 days?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!